Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersMichael Pourdehnad, Davide Ruggero, Morgan Truitt et al.|Proceedings of the National Academy of Sciences|2013Cited by 297
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Nehal J. Lakhani et al.|Annals of Oncology|2024Cited by 66